Clinical Trial

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Name: Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors — clinical trial record (NCT07327411)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a single-arm, multi-center, prospective clinical study aimed at exploring the efficacy and safety of cetuximab β combined with PRaG regimen in rescuing patients with EGFR-positive advanced refractory solid tumors.

Trial Details

NCT Number	NCT07327411
Lead Sponsor	Second Affiliated Hospital of Soochow University
Conditions	Advanced Refractory Solid Tumors
Enrollment	40 participants
Start Date	2025-12-27
Primary Completion	2027-02-10 (estimated)
Study Completion	2027-11-10 (estimated)
Updated on ClinicalTrials.gov	2026-01-08